Skip to main content
Equibles
PASG logo

PASG · Passage BIO, Inc. · Metrics

Track PASG — free

Use PASG with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PASG.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.86 -0.14 (-2.80%) At close · Sep 14
Rebalance outlook locked
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As a result, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.”
View the 10-Q filed Aug 10, 2026
Market Cap
$16.09M
Shares
3.22M

PASG metrics

51 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.86
Market cap
$16.09M

Price action

20 metrics
Price change (1W)
+7.5%
Price change (30D)
+10.1%
Price change (3M)
-13.9%
Price change (6M)
-32.9%
Price change (YTD)
-57.6%
Price change (1Y)
-28.3%
Trailing year
Price change (5Y)
—
52-week high
$19.85
52-week low
$4.08
Change from 52-week high
-74.8%
Change from 52-week low
+22.5%
Annualized volatility
111.1%
Annualized volatility (3M)
76.8%
Beta
2.8
RSI (14D)
61.4
Price vs SMA 50
+7.7%
Price vs SMA 200
-33.7%
Avg volume (3M)
66,162
Relative volume
0.1
Average dollar volume
$332,745

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
3.22M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
3.6
reciprocal yield 27.7%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-224.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-05-13

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$39.02M
Net income (TTM)
−$36.11M
Trailing 12 months
Diluted EPS (TTM)
$-11.32
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$5.89

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-810.4%
Return on assets
-143.4%
Debt / equity
—
Current ratio
1.2
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$24.16M
Latest balance sheet
Cash & equivalents
$24.16M
Total assets
$25.18M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$33.50M
Capital expenditures (TTM)
—
R&D (TTM)
$17.16M
SG&A (TTM)
—
Stock compensation (TTM)
$2.30M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
29
13F filer change QoQ
-6
Institutional ownership
43.5%

Short interest

3 metrics
Short interest
3.2%
Latest settlement · 5.2 days to cover
Days to cover
5.2d
Short-squeeze score
48 / 100

Insider activity

2 metrics
Net insider buying (90D)
$206,101
Insider-sentiment score
87 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1787297 CUSIP 702712209 Visit website Investor relations